- Open Access
CD98hc (SLC3A2) drives integrin-dependent renal cancer cell behavior
© Poettler et al.; licensee BioMed Central Ltd. 2013
Received: 1 October 2013
Accepted: 29 November 2013
Published: 21 December 2013
Overexpression of CD98hc (SLC3A2) occurs in a variety of cancers and is suspected to contribute to tumor growth. CD98, a heterodimeric transmembrane protein, physically associates with certain integrin β subunit cytoplasmic domains via its heavy chain, CD98hc. CD98hc regulates adhesion-induced intracellular signal transduction via integrins, thereby, affecting cell proliferation and clonal expansion. Disruption of CD98hc led to embryonic lethality in mice (E 3.5 and E 9.5) and CD98hc −/− embryonic stem cell transplantation failed to form teratomas, while CD98hc over-expression in somatic cells resulted in anchorage-independent growth. However, it is unclear whether interference with CD98hc expression tumor cell behavior.
Renal cell cancer cell lines have been used to determine the effect of CD98hc expression on cancer cell behavior using cell adhesion, cell trans-migration and cell spreading assays. Flow cytometric analysis was performed to study the rate of apoptosis after detachment or serum starvation. shRNA-lentiviral constructs were used to stably knockdown or reconstitute full length or mutated CD98hc. The role of CD98 as a promotor of tumorigenesis was evaluated using an in in vivo tumor transplantation animal model. Immunohistochemical analysis was performed to analyze cell proliferation and CD98 expression in tumors.
This report shows that CD98hc silencing in clear cell renal cancer cells reverts certain characteristics of tumorigenesis, including cell spreading, migration, proliferation and survival in vitro, and tumor growth in vivo. Acquisition of tumorigenic characteristics in clear cell renal cancer cells occurred through the integrin binding domain of CD98hc. A CD98hc/integrin interaction was required for adhesion-induced sustained FAK phosphorylation and activation of the major downstream signaling pathways PI3k/Akt and MEK/ERK, while overexpression of a constitutive active form of FAK rescued the CD98hc deficiency.
In this study we demonstrate that loss of CD98hc blocks tumorigenic potential in renal cell cancer.
Cytotoxic therapy is the only treatment available for many malignant diseases. However, molecular target therapies have recently become an additional and/or alternative therapeutic option. Biologic treatment is thought to be more specific, thereby resulting in fewer side effects. Renal cell cancer is a prominent representative for the efficiency of molecular target treatment, and led to the introduction of bevacizumab, sorafinib, sunitinib, pazopanib, and axitinib for the treatment of this disease [1–3].
Considering that not all patients respond to this kind of treatment, and those who benefit may become resistant [4, 5], a better understanding of molecular mechanisms involved in specific tumor cell behavior is a requisite for efficient new therapeutic strategies. For example, the determination of biomarkers such as protein expression profiles might predict treatment response or prognosis. In this context, we described the heavy chain of CD98 (CD98hc), a type II transmembrane protein, as a biomarker for less differentiated and more aggressive renal cell cancers. We identified CD98hc as a marker of less differentiated clear cell renal cell cancer (ccRCC, G2-4) as well as of the less differentiated and more aggressive type 2 papillary renal cell cancer (pRCC). The benign renal tumors such as oncocytomas do not express CD98hc . Under physiological conditions, CD98hc expression is limited to proliferating cells and activated T cells. CD98hc is mandatory for development, as genetic knock-out mice are embryonically lethal between day E 3.5 and E 9.5 [7, 8]. Moreover, CD98hc −/− embryonic stem cell transplantation failed to form teratomas in mice . In vitro inhibition of CD98hc led to reduced cell growth and the induction of apoptosis in certain cell types, while overexpression of CD98hc in CHO cells resulted in anchorage-independent growth .
A functional role of CD98hc has been described in somatic cells where the cytoplasmic tail of beta integrin adhesion receptors was prerequisite for adhesion-induced signal transduction and integrin-mediated cell behavior in embryonic stem cells and fibroblasts [10–14]. In detail, CD98hc binds to a highly conserved C-terminal domain of integrin β1A and β3 cytoplasmic subunits, thereby affecting the integrin signaling cascade. In contrast, CD98hc does not interact with integrins β1D or β7 . Furthermore, clustering CD98hc activates multiple integrin-dependent functions and mimics β1 integrin co-signaling in T-cells. Although cell adhesion is dispensable for both tumor cell- survival and -proliferation, mutation in beta integrins disrupts tumorigenesis . Furthermore, deletion studies of integrins have demonstrated that the extracellular domain of integrins is dispensable, while the cytoplasmic domain is essential for tumor growth [15–17]. This is consistent with our previous findings that CD98hc directly interacts with the cytoplasmic domain of β1 or β3 tails . The light chain of CD98 reconciles amino acid transport activity  and is covalently linked via disulfide bridges to CD98hc. The heavy chain is thereby essential to traffic the CD98 light chains to the cytoplasmic membrane .
Based on our recent data, we hypothesized that high expression of CD98hc influences malignant tumor cell behavior. We identified that CD98hc mediates tumor transplant growth in vivo. Utilizing both, gain and loss of function experiments in vitro, we also found that CD98hc is a major regulator of tumor cell behavior, thereby affecting tumor cell migration, proliferation, spreading and survival in vitro. The integrin-interacting domain of CD98hc was thereby crucial as truncation mutants were incapable to rescue CD98hc deficiency. Our data provides the first evidence that a biomarker, which is consistently over-expressed in high malignant renal cell cancers, bears a central functional role in integrin-dependent signal transduction and tumor cell behavior.
CD98hc expression affects RCC growth in vivo
Thus, we generated a stable low CD98hc expressing ccRCC cell line (lowCD98hc/CaKi2) as well as a control high CD98hc expressing ccRCC cell line (highCD98hc/CaKi2) by the use of a CD98hc mRNA targeting shRNA and scrambled control bearing lentiviral construct, respectively. A PLKO-puro1 construct, lentiviral infection of CaKi2 cells led to stable downregulation of CD98hc to 5 ± 2% of highCD98hc/Caki2. When each stable cell lines were transplanted into athymic nude mice, a significantly enhanced tumor growth was only observed in the CD98hc over-expressing tumor transplants on day 8 (135 ± 21 mg in highCD98hc/Caki2 vs. 12 ± 9 mg in lowC98hc/Caki2 tumors, n = 5 mice/group) (Figure 1B). This was reflected by the enhanced immunoreactivity of an antibody against the proliferating cell nuclear antigen (PCNA), which represents a proliferation marker, in the highCD98hc expressing tumors cells, while the immunoreactivity in the lowCD98hc/CaKi2 transplants was faint (Figure 1C).
Regulation of CD98hc expression in clear cell renal cancer cells
Having shown that expression of CD98hc expression is accompanied by tumor growth, we aimed to analyze causal underlying subcellular mechanisms. Various siRNA constructs were synthesized and applied in established renal cell cancer cell lines, such as CaKi1, CaKi2 or A-498 . Although highest transfection efficacy was obtained in CaKi2 cells, key experiments revealed consistent results in all cancer cell lines used.
CD98hc regulates integrin-dependent cell functions in ccRCC
LowCD98hc/Caki2 cells had an impaired cell spreading behavior when seeded on the integrin -β1/-β3 matrix fibronectin (Figure 3B), an effect which engages integrin-induced Rac and CDC42 activation . Furthermore, ccRCC cell transmigration was affected by CD98hc expression, because the 4 hours transmigration rate of lowCD98hc/CaKi2 cells was decreased to 19 ± 2%, 24 ± 7% after 12 hours and 41 ± 4% after 24 hours when compared to highCD98hc/Caki2 cells (Figure 3C).
Tumor cell proliferation is another hallmark in tumor propagation. As the in vivo tumor proliferation analysis (Figure 1C) suggested a proliferation dependency on CD98hc expression, we were next interested in a potential regulation of CD98hc in ccRCC cell proliferation in vitro. By a 3H-thymidin incorporation assay a reduction to 52 ± 3% after 24 h was observed in lowCD98hc/Caki2 (Figure 3D). A prerequisite of metastasis formation is adhesion independent cell survival (anti- anoikis) as well as survival upon serum-starvation. High CD98hc/Caki2 cells were characterized by sustained cell survival, while low CD98hc expressing Caki2 cells were more prone to anoikis or apoptosis (Figure 3E).
From these data we conclude that CD98hc expression is essential for malignant ccRCC behavior including cell spreading, cell migration, cell proliferation and cell survival.
The cytoplasmic domain of CD98hc is responsible for malignant tumor growth in vivo
By stable expressing these mutants in lowCD98hc/CaKi2 cells, we tested the functional role of CD98hc in vivo using tumor transplant assays. Reconstitution of wild type CD98hc in lowCD98hc/Caki2 by silCD98hc led to a similar rate in tumor growth as compared to highCD98hc/Caki2.
The single point mutations, lacking interaction with the amino acid transporters, only partly reconstituted for tumor growth, while the reconstitution with the truncation mutant lacking integrin interaction (trunsilCD98hc) failed to improve the tumor growth rate (Figure 4B).
Time-dependent tumor growth was consistently accompanied with immunoreactivity of an anti-PCNA antibody binding, reflecting cell proliferation in vivo (Figure 4C). From these data we conclude that CD98hc is essential for efficient in vivo tumor growth, whereby the cytoplasmic domain of CD98hc, which is thought to interact with integrin cytoplasmic domains thereby mediating adhesion induced signaling transduction is essential, while interaction with the CD98 amino acid transporter only partly contributed to efficient tumor growth.
The cytoplasmic domain of CD98hc is essential for integrin-induced ccRCC cell behavior
When we tested, however, for integrin signaling-dependent cell spreading, we found that the low as well as the trunsilCD98hc Caki2 cells had a diminished spreading behavior. TrunsilCD98hc expression in Caki2 cells, which lack CD98hc interaction with the integrin β tails, could not rescue the integrin specific cell spreading behavior of lowCD98hc/Caki2. In contrast, poinsilCD98hc Caki2 cells had a similar spreading behavior as highCD98hc/Caki2 cells or silCD98hc/Caki2 cells (Figure 4B). Consistently, other integrin-induced cell behavior properties such as transmigration of CaKi2 cells were also dependent on the N – terminal domain of CD98hc, because trunsilCD98hc Caki2 cells could not reconstitute the high CD98hc phenotype (Figure 4C).
By studding either highCD98hc/Caki2 cells, lowCD98hc/Caki2 cells, silCD98hc/Caki2 cells, trunsilCD98hc/Caki2 or poinsilCD98hc/Caki2 cells for tumor cell proliferation, we found that only the wild-type CD98hc reconstituting mutant silCD98hc could completely rescue the high proliferative phenotype (93 ± 4% after 24 h and 98 ± 2% after 48 h of high CD98hc Caki2, p < 0.001). In contrast, the truncation mutant bearing cells (trunsilCD98hc/Caki2) had a similar proliferation character as lowCD98hc/Caki2 cells (trunsilCD98hc 49 ± 1% after 24 h and 53 ± 2% after 48 h of silCD98hc; lowCD98hc/Caki2 cells with 38 ± 3% after 24 h and 49 ± 5% of highCD98hc Caki2 cells after 48 h, p < 0.001 (24 h) and p < 0.001 (48 h)). The poinsilCD98hc/Caki2 cells, however, had a non-significant (p = 0.75) trend for a diminished proliferative activity when compared to highCD98hc/CaKi cells (77 ± 2% of silCD98hc after 24 h and 86 ± 4% of silCD98hc after 48 h). The cytoplasmic domain of CD98hc might thus play a major role in renal cancer cell proliferation most likely via previously described interaction with integrin β tails  (Figure 5D).
Finally, we tested the mutants for cell survival upon starvation as well as upon cell detachment. Thus, we found that silCD98hc as well as poinsilCD98hc could reconstitute for high CD98hc expression, while the truncation mutant trunsilCD98hc showed a similar apoptosis behavior as the low CD98hc Caki2 cells (Figure 5E). From these data we conclude that the cytoplasmic domain of CD98hc is essential for mediating tumor cell function as it affects cell spreading, cell transmigration, cell proliferation and cell survival.
Cytoplasmic domain of CD98hc is responsible for integrin-induced signal transduction and cell spreading
To analyze whether integrin-induced signal transduction is indeed responsible for CD98hc-dpendent tumor cell behavior, we next overexpressed dominant active FAK. Integrin-induced FAK phosphorylation was shown to be dependent on the direct interaction of CD98hc with a conserved domain of the cytoplasmic tail of beta-1 integrins , thus overexpression of active FAK is thought of rescue CD98hc deficiency. highCD98hc/Caki2 or low highCD98hc/Caki2 were transiently transfected with dominant active FAK or empty vector. While with the control vector transfected lowCD98hc/Caki2 cells had a significant reduced spreading phenotype when compared to the control vector infected highCD98hc/CaKi2 cells, active FAK was capable to rescue for CD98hc deficiency. These data suggest FAK as a downstream effector of CD98hc in tumor cell behavior (Figure 6B).
Recent advances in our understanding of the complex molecular mechanism for malignant transformation, tumor growth, and propagation have led to a much more complex set of challenges for diagnostic or therapeutic strategies than originally anticipated. Among the drivers of malignant growth, receptor tyrosine kinases, functional activating molecular mutations, as well as integrin adhesion receptors are thought to be the major contributors of tumorigenesis. In this context the integrin-interacting molecule CD98hc, a type II transmembrane glycoprotein, was demonstrated to lead to malignant transformation, whereby CD98hc acted as an oncogene stimulating molecule leading to anchorage– independent growth within CHO cells .
Further evidence of the pivotal role of CD98hc in malignant growth was provided by an embryonic stem (ES) cell transplantation model, whereby only wild type CD98hc expressing embryonic stem cells formed teratomas, while CD98hc deficient embryonic stem cells showed a significant reduction in proliferation as well as reduced cell survival characteristics, thereby leading to diminished tumor growth . We recently demonstrated that CD98hc expression is mainly found in the less differentiated and more aggressive renal cell cancer subtypes such as type II papillary renal cell cancer or clear cell renal cell cancer . Our analysis of tumor tissue sections from ccRCC patients demonstrated a significant correlation between CD98hc expression and grade of malignancy (Figure 1A).
Based on these and previous observations, we hypothesized that CD98hc is a major driver of malignant tumor cell behavior and aimed to characterize any pivotal functional role of CD98hc in tumor cell biology. Thus, we first generated either high expressing CD98hc or very low CD98hc expressing ccRCC cell lines to analyze malignant cell behavior as well as the molecular pathways responsible for CD98hc mediated tumor cell functions.
In order to test whether CD98hc plays a role within renal cell carcinoma biology, we xeno-transplanted highCD98hc/Caki2 cells or lowCD98hc/Caki2 cells into nude mice. We observed a striking difference in tumor growth and subsequent loss of anti-PCNA immunoreactivity. This suggested that CD98hc regulates tumor cell proliferation (Figure 1B). Moreover, we were able to exclude any effect of CD98hc on integrin expression or integrin-ligand binding capacities (Figure 2B, Figure 3A). This is consistent with previous observations that CD98hc does not affect integrin expression or activation , but mediates adhesion-induced signal transduction (outside-in signaling). This is most likely induced by direct interaction of the cytoplasmic domain of CD98hc with a conserved motif of the C-terminal end of integrin beta-tails, which is a prerequisite for efficient FAK phosphorylation upon cell adhesion . Although not proven, it is tempting to speculate that CD98hc might promote complex formation of most upstream signaling molecules such as member of the src-family kinases, FAK or others. We were interested whether CD98hc-dependent tumor growth in vivo was mediated via integrin-induced signal transduction (outside-in) or CD98hc-dependent amino acid transportation via its light chains. When we first examined integrin-mediated cell behavior, such as cell spreading, cell migration or anoikis, the so called apoptosis upon cell detachment, we found that all these cell functions were dependent on CD98hc-expression. This was an important observation as it was unclear whether these tumor cell functions were affected by CD98hc. Our data suggest that CD98hc, when over-expressed, augments malignant cell behavior, such as tumor cell spreading, transmigration, proliferation, or cell survival. All these functions are thought to be hallmarks for circulating tumor cell survival and metastasis formation.
Although integrin-dependent cell functions were strongly affected by CD98hc expression, were still interested whether the cytoplasmic integrin-interaction domain [9, 18] or the cysteine-bridges to the amino-acid transporting light chains of CD98hc were dispensable for malignant tumor cell behavior. We generated silent mutations, which were not recognized by shRNA constructs, in order to rescue CD98hc expression in lowCD98hc ccRCC cells. We also introduced either cytoplasmic domain-truncation mutants (trunsilCD98hc) or mutants which lack the light chain interaction (poinsilCD98hc). We found that the major steps of malignant cell behavior were dependent on the cytoplasmic tail of CD98hc, among them tumor cell migration, cell spreading, cell proliferation as well as cell survival. In contrast, the amino acid transport activity partly affected cancer cell proliferation in vitro and in vivo, which was not statistically significant (p-value high CD98hc vs. poinsilCD98hc p = 0.12). Finally, our in vitro findings were also reflected by in vivo tumor transplantation assays (Figure 4).
One could speculate that the interaction partners for CD98hc beta 1 integrins as well as beta 3 integrins, which are both expressed in CaKi2 cells and have previously been shown to interact with CD98hc [9, 10], were mediating adhesion-induced signal transduction via induction of FAK and c-src whenever CD98hc was present. This is also supported by the fact that whenever the cytoplasmic domain of CD98hc for integrin binding was absent, for instance in CD98hc reconstituted cells, a diminished FAK phosphorylation upon cell adhesion on a beta 1 integrin as well as beta 3 integrin-specific matrix protein was observed.
Furthermore, overexpression of dominant active FAK rescued the low CD98hc spreading phenotype. This is of special importance in respect to previous findings that malignancy of certain tumor cells depends on activation of upstream integrin signaling events . This is also consistent with our in vivo findings that the absence of the cytoplasmic domain of CD98hc, which was demonstrated to be responsible for efficient integrin-induced signal transduction , led to a significant reduction in tumor growth. In a previous study, we analyzed CD98hc expression in various tumor cell lines and found that CD98hc is frequently expressed in aggressive tumor cells derived from adenocarcinomas of the lung, colon and breast . Therefore, CD98hc expression is significantly associated with more aggressive and less differentiated G3, G4 ccRCC (Figure 1A) and supports the observation of an enhanced activation state within tumor cells. Whether ccRCC metastasis formation generally depends on CD98hc expression was not the focus of this study and is currently being investigated.
In conclusion, by a combination of different in vitro and in vivo attempts, we aimed to define a potential functional role of CD98hc in renal cell cancer. We observed a correlation between less differentiated and more aggressive clear cell renal cell cancer and CD98hc expression. We found that CD98hc is not only a descriptive marker for aggressive cancers, but bears a major regulatory role of malignant cell function. This was demonstrated by knock down and reconstitution in vivo and in vitro, thereby suggesting that the integrin interacting domain of CD98hc is required for the malignant phenotype of renal cancer cells. It is tempting to speculate, that these novel insights will lead to more effective strategies in cancer treatment.
Caki-2 cells were cultured in RPMI 1640 (10% FBS and 5% Penicillin/Streptomycin). 24 hours prior to experiments cells were maintained in antibiotic free medium under serum reduced conditions (5% FBS). Experiments were performed under serum-free conditions.
Downregulation of CD98hc and production of lentiviral particles
CD98hc siRNA was purchased from Santa Cruz-Biotechnology and used according to manufactures instructions. Primers for shRNA CD98hc were purchased from Invitrogen. Annealed oligos were cloned AgeI/EcoRI to pLKO-puro1. pLKO.1 TRC Cloning Vector and reagents were used from Addgene and carried out according to the manufactures guidelines. Cells were coated on polyprene (10 μg/ml) prior to lentiviral application, medium was changed after 24 hours and protein quantification was performed after 48 hour. For generation of stable lowCD98hc or highCD98hc/Caki2 (scrambled shRNA) cells were grown in the presence of puromycin (5 μg/ml) for at least two weeks.
Reconstitution of CD98hc by silent mutations was performed utilizing a QuickChange-Kit (Stratagene) using a pcDNA 3.1 Vector. The cytoplasmic truncation mutant (trunsilCD98hc), the deltaWALLL truncation nucleotide 1–87, has been described before  and was generated to interfere with integrin interaction. The Cys109 and Cys330 (poinsilCD98hc) were performed as described by Fenczik, 2001 . Constructs were cloned in pBABE via ECO-RI [20, 24]. All numbering uses the amino acid sequence reported in entry 4F2_human (P08195-1) of the Swiss-Prot data base as of January, 2010.
Transient transfection of HEK-293 cells and retroviral infection of lowCD98hc Caki2 cells were performed as described before . Stable infectants were selected in growth medium containing 1 mg/ml puromycin.
50 μl normal medium was transferred in 96-well plate and incubated at 37°C. Cells were harvested with Trypsin/EDTA and cell number was counted. 5000cells/well were transferred in 96-wells and incubated for 24 or 48 hours. 15 μl Dye solution was then added and again incubated 4 hours. 100 μl Solubilisation-/Stop-solution was added and after 2 hours at room temperature absorption was measured in a photometer at 750 nm.
Counting – assay
Cells were harvested with trypsin/EDTA as described above; 1000, 2000 or 5000 cells were transferred in each plate (96well) before cells of 10 fields of a raster ocular (1 field = 1 mm2) were counted under light microscope after one hour adhesion time and counted again after 24 and 48 hours.
Different concentrations of lowCD98hc/Caki2 cells or control cells were seeded in a 96well plate with medium (RPMI + 10% FCS + 1% P/S). After 18 h cells were treated with 50 μl per well thymidine (H3 : RPMI = 1:10) 1 h, 37°C, 5%CO2 before cells were washed and lysed. Incorporated 3H-thymidine was then detected by liquid scintillation.
Cell migration was assayed in a modified Boyden chamber-system by using transwell membranes (8 μm) coated with 1% gelatin. Cells were seeded on the top of the membrane in medium without FCS, while in the lower chamber 10% FCS was added as a stimulus. After four hours filters were washes with PBS ×1, fixed (Methanol: acetic acid, 3 : 1) and nuclear stained with DAPI. Migrated cells in the lower chamber were counted using an AX70 Olympus-microscope and compared to controls (absolute numbers per mm2 is given).
Anoikis- and starvation-assays
Poly 2-hydroxyethyl-methacrylate (polyHEMA) was used for detachment cell survival assays. PolyHEMA was diluted in 75% ethanol as described by manufacture, mixed and kept at 37°C overnight. One hour before experimental onset 110 μl of PolyHEMA was added in 24- well plates and air dried at room temperature. 1×106 cells were then transferred in prepared 24- well plates and after 24 or 48 hours incubation time apoptosis upon detachment was measured. For cell starvation, 1% BSA for 24 or 48 hours at 37°C, 5%CO2 was used.
Cells were stained with Annexin V-FITC Detection Kit (Alexis Biochemicals, Farmingdale, NY) and propidium iodide to estimate apoptosis and necrosis via flow cytometry (FACSCalibur, BD).
Cell adhesion and spreading
Assays of cell spreading were either performed on 20 μg/ml fibrinogen (Fg) or 10 μg/ml fibronectin (FN) or 10 μg/ml Poly-D-Lysine (Millipore) as described previously . The cells were allowed to attach for 30 minutes for adhesion assay before plates were washed with phosphate-buffered saline (PBSx1); attached cells were fixed with 3.7% formaldehyde and stained with crystal violet. Photographic images were acquired with Olympus SC20-CCD on a bright-field microscopy. Cells that exhibited flattening and the presence of lamellipodia under microscope examination were scored as spreading cells. Cell area was assessed by Image J1.32 software (National Institutes of Health).
[14C]- Leucine (50 μCi) was purchased from Perkin Elmer, normal L-leucine from Sigma. 2× 105 lowCD98hc/- or highC98hc/Caki2 cells were washed tree times in a Na- free Solution (125 mM Cholin Cl, 4,8 mM KCl, 1,3 mM CaCl2, 1,2 mM MgSO4, 25 mM Hepes-Tris, 1,2 mM KH2PO4, 5,6 mM Glucose, pH 7,4) than 20 mM L-Leucine/[14C]- Leucine was added to Na- free solution for 1 min or 10 min, washed with Na free Uptake solution and lysed with 50 μl RIPA-Buffer. After transferring lysates in scintillation plates, 100 μl scintillator-liquid was added and [14C] - Leucine uptake was measured via a scintillator.
In vivo transplant assay
HighCD98hc/Caki2, lowCD98hc/Caki2, silC98hc/Caki2, poinsilCD98hc/Caki2 and trunsilCD98hc/Caki2 cells were xenotransplanted into 8 weeks old nude mice by subcutaneous injection (s.c.) into the right flank, five animals per group. After 8 days mice were sacrificed and tumors were extracted and embedded in mounting medium. 4 micrometer sections were stained immunohistochemically for 4'-6-diamidino-2-phenylindole (DAPI), CD98hc (C-20): sc- 7095 (Santa Cruz Biotechnology, CA) or PCNA (Abcam, UK).
The study included 51 paraffin-embedded ccRCCs, from kidney origin. All tumors were derived from a well characterized tissue bank of the Department of Clinical Pathology, Medical University of Vienna. Specimens were sliced before they were routinely fixed overnight with 4.5% buffered formaldehyde and stained for CD98hc as described previously . ccRCCs were classified according to the TNM-System (T = Tumor, N = Node, M = Metastases according to the Unio Internationalis Contra Cancrum, UICC) , and graded according to Fuhrman et al. . None of the patients had been treated with chemotherapy, tyrosine kinase inhibitors or immunotherapy prior to surgery.
Detailed information about Material and Methods is located within Additional file 1.
The project was supported by “Initiative-Krebsforschung”-Foundation and FWF-Austrian-Science-Fund (P23199). Special thanks to Mark H. Ginsberg (UCSD) for suggesting, supervising and discussing the integrin-experiments and carefully editing the manuscript. We thank our colleague Kyle Williams, a US-citizen and native speaker, for language proof.
- Rini BI: Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet. 2011, 378 (9807): 1931-1939. 10.1016/S0140-6736(11)61613-9View ArticlePubMedGoogle Scholar
- Turnbull JD, Cobert J, Jaffe T, Harrison MR, George DJ, Armstrong AJ: Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors. Clin Genitourin Cancer. 2013, 11: 45-50. 10.1016/j.clgc.2012.06.001View ArticlePubMedGoogle Scholar
- Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A: Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer. 2012, 107: 1665-1671. 10.1038/bjc.2012.385PubMed CentralView ArticlePubMedGoogle Scholar
- Mulders PF: Renal cell carcinoma. World J Urol. 2008, 26: 113- 10.1007/s00345-008-0248-1View ArticlePubMedGoogle Scholar
- Rini BI, Rathmell WK, Godley P: Renal cell carcinoma. Curr Opin Oncol. 2008, 20: 300-306. 10.1097/CCO.0b013e3282f9782bView ArticlePubMedGoogle Scholar
- Prager GW, Poettler M, Schmidinger M, Mazal PR, Susani M, Zielinski CC: CD98hc (SLC3A2), a novel marker in renal cell cancer. Eur J Clin Invest. 2009, 39: 304-310. 10.1111/j.1365-2362.2009.02096.xView ArticlePubMedGoogle Scholar
- Feral CC, Nishiya N, Fenczik CA, Stuhlmann H, Slepak M, Ginsberg MH: CD98hc (SLC3A2) mediates integrin signaling. Proc Natl Acad Sci USA. 2005, 102 (2): 355-360. 10.1073/pnas.0404852102PubMed CentralView ArticlePubMedGoogle Scholar
- Tsumura H, Suzuki N, Saito H, Kawano M, Otake S, Kozuka Y: The targeted disruption of the CD98 gene results in embryonic lethality. Biochem Biophys Res Commun. 2003, 308: 847-851. 10.1016/S0006-291X(03)01473-6View ArticlePubMedGoogle Scholar
- Henderson NC, Collis EA, Mackinnon AC, Simpson KJ, Haslett C, Zent R: CD98hc (SLC3A2) interaction with beta 1 integrins is required for transformation. J Biol Chem. 2004, 279: 54731-54741. 10.1074/jbc.M408700200View ArticlePubMedGoogle Scholar
- Rintoul RC, Buttery RC, Mackinnon AC, Wong WS, Mosher D, Haslett C: Cross-linking CD98 promotes integrin-like signaling and anchorage-independent growth. Mol Biol Cell. 2002, 13: 2841-2852. 10.1091/mbc.01-11-0530PubMed CentralView ArticlePubMedGoogle Scholar
- Fenczik CA, Sethi T, Ramos JW, Hughes PE, Ginsberg MH: Complementation of dominant suppression implicates CD98 in integrin activation. Nature. 1997, 390: 81-85. 10.1038/36349View ArticlePubMedGoogle Scholar
- Zent R, Fenczik CA, Calderwood DA, Liu S, Dellos M, Ginsberg MH: Class- and splice variant-specific association of CD98 with integrin beta cytoplasmic domains. J Biol Chem. 2000, 275: 5059-5064. 10.1074/jbc.275.7.5059View ArticlePubMedGoogle Scholar
- Merlin D, Sitaraman S, Liu X, Eastburn K, Sun J, Kucharzik T: CD98-mediated links between amino acid transport and beta 1 integrin distribution in polarized columnar epithelia. J Biol Chem. 2001, 276: 39282-39289. 10.1074/jbc.M105077200View ArticlePubMedGoogle Scholar
- Miyamoto YJ, Mitchell JS, McIntyre BW: Physical association and functional interaction between beta1 integrin and CD98 on human T lymphocytes. Mol Immunol. 2003, 39: 739-751. 10.1016/S0161-5890(02)00255-9View ArticlePubMedGoogle Scholar
- Stroeken PJ, van Rijthoven EA, Boer E, Geerts D, Roos E: Cytoplasmic domain mutants of beta1 integrin, expressed in beta 1-knockout lymphoma cells, have distinct effects on adhesion, invasion and metastasis. Oncogene. 2000, 19: 1232-1238. 10.1038/sj.onc.1203423View ArticlePubMedGoogle Scholar
- Filardo EJ, Brooks PC, Deming SL, Damsky C, Cheresh DA: Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol. 1995, 130: 441-450. 10.1083/jcb.130.2.441View ArticlePubMedGoogle Scholar
- Parsons M, Keppler MD, Kline A, Messent A, Humphries MJ, Gilchrist R: Site-directed perturbation of protein kinase C– integrin interaction blocks carcinoma cell chemotaxis. Mol Cell Biol. 2002, 22: 5897-5911. 10.1128/MCB.22.16.5897-5911.2002PubMed CentralView ArticlePubMedGoogle Scholar
- Prager GW, Feral CC, Kim C, Han J, Ginsberg MH: CD98hc (SLC3A2) Interaction with the Integrin beta Subunit Cytoplasmic Domain Mediates Adhesive Signaling. J Biol Chem. 2007, 282: 24477-24484. 10.1074/jbc.M702877200View ArticlePubMedGoogle Scholar
- Haynes BF, Hemler ME, Mann DL, Eisenbarth GS, Shelhamer J, Mostowski HS: Characterization of a monoclonal antibody (4 F2) that binds to human monocytes and to a subset of activated lymphocytes. J Immunol. 1981, 126: 1409-1414.PubMedGoogle Scholar
- Fenczik CA, Zent R, Dellos M, Calderwood DA, Satriano J, Kelly C: Distinct domains of CD98hc regulate integrins and amino acid transport. J Biol Chem. 2001, 276: 8746-8752. 10.1074/jbc.M011239200View ArticlePubMedGoogle Scholar
- Fogelstrand P, Feral CC, Zargham R, Ginsberg MH: Dependence of proliferative vascular smooth muscle cells on CD98hc (4F2hc, SLC3A2). J Exp Med. 2009, 206: 2397-2406. 10.1084/jem.20082845PubMed CentralView ArticlePubMedGoogle Scholar
- Boulter E, Estrach S, Errante A, Pons C, Cailleteau L, Tissot F: CD98hc (SLC3A2) regulation of skin homeostasis wanes with age. J Exp Med. 2013, 210: 173-190. 10.1084/jem.20121651PubMed CentralView ArticlePubMedGoogle Scholar
- Price LS, Leng J, Schwartz MA, Bokoch GM: Activation of Rac and Cdc42 by integrins mediates cell spreading. Mol Biol Cell. 1998, 9: 1863-1871. 10.1091/mbc.9.7.1863PubMed CentralView ArticlePubMedGoogle Scholar
- Cai S, Bulus N, Fonseca-Siesser PM, Chen D, Hanks SK, Pozzi A: CD98 modulates integrin beta1 function in polarized epithelial cells. J Cell Sci. 2005, 118: 889-899. 10.1242/jcs.01674View ArticlePubMedGoogle Scholar
- Pear WS, Nolan GP, Scott ML, Baltimore D: Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA. 1993, 90: 8392-8396. 10.1073/pnas.90.18.8392PubMed CentralView ArticlePubMedGoogle Scholar
- Liu S, Thomas SM, Woodside DG, Rose DM, Kiosses WB, Pfaff M: Binding of paxillin to alpha4 integrins modifies integrin-dependent biological responses. Nature. 1999, 402: 676-681. 10.1038/45264View ArticlePubMedGoogle Scholar
- Sobin LH, International Union Against Cancer: TNM Classification of Malignant Tumors. 2002, 180-183. New York: Wiley, 6Google Scholar
- Fuhrman SA, Lasky LC, Limas C: Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982, 6: 655-663. 10.1097/00000478-198210000-00007View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.